Carboxyamidotriazole in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

• Status: Completed
• Trial end date: 2007-10-01
• Target enrollment: 0
• Participant gender: Female

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of carboxyamidotriazole in treating patients with refractory or recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cancer Institute (NCI)
• Treatments: Carboxyamido-triazole

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed refractory or recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer

• Measurable disease by physical exam, radiography, peritoneoscopy, or laparoscopy

• No more than 4 weeks since prior peritoneoscopy

• No brain metastases

PATIENT CHARACTERISTICS:

Age:

• 18 and over

Performance status:

• ECOG 0-2

Life expectancy:

• At least 4 months

Hematopoietic:

• Absolute neutrophil count at least 1,000/mm^3

• Platelet count at least 100,000/mm^3

• Hemoglobin at least 9.0 g/dL AND/OR

• Hematocrit at least 27%

Hepatic:

• SGOT/SGPT no greater than 3 times upper limit of normal

• Bilirubin normal

Renal:

• Creatinine no greater than 1.5 mg/dL OR

• Creatinine clearance at least 50 mL/min

Cardiovascular:

• No history of symptomatic cardiac dysrhythmias requiring medication

• At least 6 months since prior myocardial infarction

• No unstable or newly diagnosed angina

Pulmonary:

• No obstructive lung disease requiring oxygen therapy

Other:

• Not pregnant or nursing

• HIV negative

• Must be able to take oral medication

• No concurrent medical condition (e.g., impending bowel obstruction)

• No grade 2 or greater residual peripheral neuropathy

• No active infection

• No other prior or concurrent invasive malignancy within the past 5 years

• No history of acute visual loss other than that associated with retinal detachment

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• At least 4 weeks since prior cytokine therapy

• No concurrent cytokine therapy to maintain WBC count

Chemotherapy:

• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas, carboplatin, or mitomycin)

• No other concurrent chemotherapy

Endocrine therapy:

• At least 4 weeks since prior hormonal therapy

• No concurrent corticosteroids at doses greater than physiological replacement doses

• No concurrent hormonal therapy

Radiotherapy:

• At least 4 weeks since prior radiotherapy

• No concurrent radiotherapy

Surgery:

• See Disease Characteristics

Other:

• No more than 3 prior treatment regimens

• At least 1 week since prior systemic antibiotics for infection

• No chronic antifungal treatment with antimycotic imidazoles

• No concurrent alternative therapies